Analysis

Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis

Vertex Pharmaceuticals Incorporated investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to VRTX.

websiteVRTX/analysis/VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to VRTX.

Stock profile

Ticker

VRTX

Asset type

Stock

Market cap

$112.92B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Vertex Pharmaceuticals Incorporated may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • VRTX primary listing
  • VX1
  • 882807
  • VRTX34
  • 0QZU
  • 4VRTX
  • VRTXD
  • 1VRTX

Latest Vertex Pharmaceuticals Incorporated news

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Ass...

BOSTON, June 11, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peop...

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA

Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Sever...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that Health Canada has accepted for review a New Drug Submission (NDS) for suzetrigine for the treatment of moderate-to-sev...

Research sections

Valuation

Review valuation context for Vertex Pharmaceuticals Incorporated.

Future growth

Review future growth context for Vertex Pharmaceuticals Incorporated.

Past performance

Review past performance context for Vertex Pharmaceuticals Incorporated.

Financial health

Review financial health context for Vertex Pharmaceuticals Incorporated.

Dividend

Review dividend context for Vertex Pharmaceuticals Incorporated.

Management

Review management context for Vertex Pharmaceuticals Incorporated.

Ownership

Review ownership context for Vertex Pharmaceuticals Incorporated.

Other information

Review other information context for Vertex Pharmaceuticals Incorporated.

Community

Review community context for Vertex Pharmaceuticals Incorporated.